Water-Soluble Camptothecin Conjugates for High-DAR ADCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Camptothecin analogs used in antibody-drug conjugates suffer from low solubility, leading to aggregation and systemic side effects, limiting the Drug-to-Antibody Ratio and efficacy in existing treatments.
Innovation Solution
Development of water-soluble camptothecin analogs conjugates that are stable in circulation and exhibit high cytotoxicity upon release in disordered cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin analogs are used in antibody-drug conjugates, then cytotoxic efficacy is improved, but solubility deteriorates leading to aggregation and systemic side effects
Solution Approach 1:
The patent introduces a water-soluble linker as an intermediary component between the camptothecin analog payload and the antibody. This linker contains hydrophilic groups (such as PEG chains or charged groups) that improve the overall solubility of the conjugate without compromising the cytotoxic activity of the camptothecin analog. The linker acts as a mediator that reconciles the hydrophobic nature of the payload with the need for water solubility in biological systems.
Solution Approach 2:
The patent modifies the chemical parameters of the camptothecin analog conjugate by introducing water-soluble groups into the linker or payload structure. This changes the hydrophobicity parameter of the overall conjugate, improving its aqueous solubility. The modification maintains the cytotoxic parameter while adjusting the solubility parameter to prevent aggregation and reduce systemic side effects.
2Reliability
If camptothecin analogs are used in antibody-drug conjugates, then cytotoxic efficacy is improved, but aggregation occurs due to low solubility
Solution Approach 1:
The water-soluble linker serves as an intermediary that prevents direct interaction between hydrophobic camptothecin analog molecules, thereby preventing aggregation. The hydrophilic groups in the linker create steric and electrostatic barriers that maintain molecular dispersion in aqueous environments while preserving the biological activity of the payload.
Solution Approach 2:
The patent changes the solubility parameter of the conjugate by incorporating hydrophilic moieties, which directly addresses the aggregation problem. This parameter change ensures that the conjugate remains monodisperse and stable in circulation, preventing the formation of aggregates that would otherwise occur with hydrophobic camptothecin analogs.
3Reliability
If conventional camptothecin analogs are used, then cytotoxic activity is achieved, but Drug-to-Antibody Ratio is limited due to solubility constraints
Solution Approach 1:
The patent changes the solubility parameter of the drug payload or its linker, enabling higher concentrations of the camptothecin analog to be incorporated into the antibody conjugate without precipitation or aggregation. This parameter modification allows for increased Drug-to-Antibody Ratios, potentially improving therapeutic efficacy by delivering more cytotoxic payload per antibody molecule.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates provide improved solubility and stability, enhancing the Drug-to-Antibody Ratio and efficacy by minimizing aggregation and systemic toxicity.
Implementation Method 1
stable in circulation
Implementation Method 2
exhibit high cytotoxicity upon release
Data Source
AI summary
Provided are conjugates of novel camptothecin analogs with a cell binding molecule of formula (I). It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of application the conjugates in targeted treating of cancer.